Elsewhere in the AGA Journals
(Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - November 23, 2023 Category: Gastroenterology Source Type: research

Prolonged gastrointestinal manifestations after recovery from COVID-19
Acute enteric infections are well known to result in long-term gastrointestinal disorders. While COVID-19 is principally a respiratory illness, it demonstrates significant gastrointestinal tropism, possibly predisposing to prolonged gut manifestations. We aimed to examine the long-term gastrointestinal impact of hospitalization with COVID-19. (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - November 21, 2023 Category: Gastroenterology Authors: B. Joseph Elmunzer, Olafur S. Palsson, Nauzer Forbes, Ali Zakaria, Christian Davis, Andrew Canakis, Emad Qayed, Benjamin Bick, Swati Pawa, William M. Tierney, Caroline G. McLeod, Jason Taylor, Harsh Patel, Robin B. Mendelsohn, Gokul Bala, Ian Sloan, Ambre Source Type: research

A Liver Stiffness –Based Etiology-Independent Machine Learning Algorithm to Predict Hepatocellular Carcinoma
In this study, we developed and validated a liver stiffness –based machine learning algorithm (ML) for prediction and risk stratification of HCC in various chronic liver diseases (CLDs). (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - November 20, 2023 Category: Gastroenterology Authors: Huapeng Lin, Guanlin Li, Ad èle Delamarre, Sang Hoon Ahn, Xinrong Zhang, Beom Kyung Kim, Lilian Yan Liang, Hye Won Lee, Grace Lai-Hung Wong, Pong-Chi Yuen, Henry Lik-Yuen Chan, Stephen Lam Chan, Vincent Wai-Sun Wong, Victor de Lédinghen, Seung Up Kim, T Source Type: research

A liver stiffness-based etiology-independent machine learning algorithm to predict hepatocellular carcinoma
In this study, we developed and validated a liver stiffness-based machine learning algorithm (ML) for prediction and risk stratification of HCC in various chronic liver diseases (CLDs). (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - November 20, 2023 Category: Gastroenterology Authors: Huapeng Lin, Guanlin Li, Ad èle Delamarre, Sang Hoon Ahn, Xinrong Zhang, Beom Kyung Kim, Lilian Yan Liang, Hye Won Lee, Grace Lai-Hung Wong, Pong-Chi Yuen, Henry Lik-Yuen Chan, Stephen Lam Chan, Vincent Wai-Sun Wong, Victor de Lédinghen, Seung Up Kim, T Source Type: research

Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 Trial
Histologic evaluation of mucosal healing in Crohn ’s disease (CD) is an evolving treatment target. We evaluated histologic outcomes for mirikizumab efficacy and associations with endoscopic and 1-year outcomes. (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - November 20, 2023 Category: Gastroenterology Authors: Fernando Magro, Marijana Protic, Gert De Hertogh, Lai Shan Chan, Paul Pollack, Vipul Jairath, Hilde Carlier, Emily Hon, Brian G. Feagan, Noam Harpaz, Rish Pai, Walter Reinisch Source Type: research

Accuracy of ChatGPT in Common Gastrointestinal Diseases: Impact for Patients and Providers
(Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - November 18, 2023 Category: Gastroenterology Authors: Anthony Kerbage, Joseph Kassab, Joseph El Dahdah, Carol A. Burke, Jean-Paul Achkar, Carol Rouphael Tags: Research Letter Source Type: research

Reply
We appreciate Dr Butler's interest in our study and concur that environmental toxins transmitted through human milk potentially could offer an explanation for the observed association between being breastfed in infancy and the increased risk of colorectal cancer, despite the challenges and scarcity of research in this area. Dr Butler particularly highlighted polyfluoroalkyl substances (PFAS), which are chemicals known for their resistance to grease, oil, water, and heat, and now are found in hundreds of modern products. (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - November 16, 2023 Category: Gastroenterology Authors: Chen Yuan, Kimmie Ng Tags: Letters to the Editor Source Type: research

Underuse of HCC Surveillance: Not a sign of cynicism
(Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - November 16, 2023 Category: Gastroenterology Authors: Amit G. Singal, Darine Daher, Karim Seif El Dahan, Ju Dong Yang, Nicole E. Rich, Neehar D. Parikh Tags: Letter to the Editor Source Type: research

Reply to Dr. Butler
(Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - November 16, 2023 Category: Gastroenterology Authors: Chen Yuan, Kimmie Ng Tags: Letter to the Editor Source Type: research

Reply
(Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - November 16, 2023 Category: Gastroenterology Authors: Molla M. Wassie, Graeme P. Young, Jean M. Winter, Charles Cock, Erin L. Symonds Tags: Letter to the Editor Source Type: research

A Composite Morphometric Duodenal Biopsy Mucosal Scale for Celiac Disease Encompassing both Morphology and Inflammation
Villus height to crypt depth ratio (Vh:Cd) and intraepithelial lymphocytes (IEL) are key measures of histology of the small intestine in celiac disease (CeD). While the field of CeD has advanced, there remains no broadly accepted measure of mucosal injury. We assessed whether a composite Vh:Cd and IEL scale (named VCIEL) can improve accuracy and statistical precision for assessing histology, compared to individual measures. (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - November 10, 2023 Category: Gastroenterology Authors: Jack A. Syage, Markku M äki, Daniel A. Leffler, Jocelyn A. Silvester, Jennifer A. Sealey-Voyksner, Tsung-Teh Wu, Joseph A. Murray Source Type: research

ENTERPRET: a randomized controlled trial of vedolizumab dose optimization in patients with ulcerative colitis who have early nonresponse
Patients with ulcerative colitis (UC) may experience nonresponse to biologics, possibly due to low drug exposure. This trial assessed the efficacy of dose optimization in patients with UC who have early nonresponse to vedolizumab and high drug clearance. (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - November 9, 2023 Category: Gastroenterology Authors: Vipul Jairath, Andres Yarur, Mark T. Osterman, Alexandra James, Diane Balma, Shailly Mehrotra, Lili Yang, Vijay Yajnik, Rana M. Qasim Khan Source Type: research

Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017 –2020
Following the Delphi consensus process, the term steatotic liver disease (SLD) was introduced to replace fatty liver disease, while the term metabolic dysfunction-associated steatotic liver disease (MASLD) emerged as the successor to the term nonalcoholic fatty liver disease (NAFLD).1 This revised nomenclature aims to enhance precision and mitigate negative connotations and potential stigmatization, while refining comprehension and disease categorization. Concurrently, a novel category was introduced to capture individuals whose alcohol consumption exceeded the previously defined thresholds of NAFLD but remained unclassifi...
Source: Clinical Gastroenterology and Hepatology - November 8, 2023 Category: Gastroenterology Authors: Markos Kalligeros, Athanasios Vassilopoulos, Stephanos Vassilopoulos, David W. Victor, Eleftherios Mylonakis, Mazen Noureddin Tags: Research Letter Source Type: research

Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: The National Health and Nutrition Examination Survey 2017 –2020
Following the Delphi consensus process, the term steatotic liver disease (SLD) was introduced to replace fatty liver disease, while the term metabolic dysfunction-associated steatotic liver disease (MASLD) emerged as the successor to the term nonalcoholic fatty liver disease (NAFLD).1 This revised nomenclature aims to enhance precision and mitigate negative connotations and potential stigmatization, while refining comprehension and disease categorization. Concurrently, a novel category was introduced to capture individuals whose alcohol consumption exceeded the previously defined thresholds of NAFLD but remained unclassifi...
Source: Clinical Gastroenterology and Hepatology - November 8, 2023 Category: Gastroenterology Authors: Markos Kalligeros, Athanasios Vassilopoulos, Stephanos Vassilopoulos, David W. Victor, Eleftherios Mylonakis, Mazen Noureddin Tags: Research Letter Source Type: research

Reply
We thank Dr Weiss for his response to our study and agree that insurer-driven hard lines based on a theoretical “average patient” and enforced without interface with the ordering physician appear problematic.1–3 In finding that strict adherence to guidelines may increase insurer and patient costs over a year, our study quantifies the rationale against blanket prior authorization requirements from all pe rspectives, advocating for flexibility of the management strategy based on the patient–physician relationship rather than replacement of a one-size-fits-all approach with another. (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - November 8, 2023 Category: Gastroenterology Authors: Eric D. Shah, Emily V. Wechsler Tags: Letters to the Editor Source Type: research